The Hippo pathway in endometrial cancer: a potential therapeutic target?

Frontiers in Oncology

Oncology

Yingmei Wang¹  Qianqian Li¹  Wenyan Tian¹  Xinyun Shen¹  Lingli Chen¹  Fengxia Xue¹  Yiqing Sun¹ 

[1] Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China;Tianjin Key Laboratory of Female Reproductive Health and Eugenics, Tianjin Medical University General Hospital, Tianjin, China;

关键词: hippo pathway;    endometrial cancer (EC);    tumor microenvironment;    drug resistance;    treatment;   

DOI  :  10.3389/fonc.2023.1273345

 received in 2023-08-06, accepted in 2023-10-09,  发布年份 2023

来源: Frontiers

【 摘 要 】

Endometrial cancer, one of the most prevalent malignant cancers tumors of the female reproductive tract, has been increasing in incidence and mortality rates around the world. The Hippo pathway, one of the eight traditional human cancer signaling pathways, is an intricate signaling network that regulates cell proliferation, differentiation, and migration as well as restricting organ size in response to a range of intracellular and extracellular signals. Inhibiting the Hippo pathway results in aberrant activation of its downstream core component YAP/TAZ, which can enhance cancer cells’ metabolism and maintain their stemness. Additionally, the Hippo pathway can modulate the tumor microenvironment and induce drug resistance, where tumorigenesis and tumor progression occur. However, the Hippo pathway has been little researched in endometrial cancer. Here, we aim to review how the Hippo pathway contributes to the onset, development and the potential treatment of endometrial cancer with the aim of providing new therapeutic targets.

【 授权许可】

Unknown   
Copyright © 2023 Shen, Li, Sun, Chen, Xue, Tian and Wang